公开(公告)号：US20250025443A1

公开(公告)日：2025-01-23

申请号：US18700786

申请日：2022-10-13

Applicant: CLEAR CREEK BIO, INC.

Inventor： John K. DICKSON ,  Joseph P. VACCA ,  Maryline KIENLE ,  Nadim SHOHDY ,  James Francis DEMAREST

IPC: A61K31/397 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/36 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/428 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4465 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61P31/14 ,  C07C233/65 ,  C07C243/32 ,  C07C255/44 ,  C07C271/16 ,  C07C311/08 ,  C07D205/04 ,  C07D207/20 ,  C07D209/32 ,  C07D211/46 ,  C07D213/74 ,  C07D215/22 ,  C07D223/04 ,  C07D231/18 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D239/34 ,  C07D241/44 ,  C07D245/02 ,  C07D277/34 ,  C07D277/64 ,  C07D295/073 ,  C07D305/08 ,  C07D317/54 ,  C07D333/20 ,  C07D333/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D411/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

Abstract: This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I″), and pharmaceutically acceptable salts thereof.

公开(公告)号：US20240287001A9

公开(公告)日：2024-08-29

申请号：US18029842

申请日：2021-10-01

Applicant: Azafaros B.V.

Inventor： Robert Hett ,  Fritz Blatter ,  Jennifer Robin ,  Kyle Landskroner

IPC: C07D211/46

CPC classification number: C07D211/46 ,  C07B2200/13

Abstract: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.

公开(公告)号：US11964942B2

公开(公告)日：2024-04-23

申请号：US17737580

申请日：2022-05-05

Applicant: Eccogene (Shanghai) Co., Ltd.

Inventor： Zaifang Ren ,  Xuefeng Sun ,  Qing Xu

IPC: C07D211/46 ,  C07C317/32 ,  C07D211/32 ,  C07D307/14 ,  C07D309/06 ,  C07D319/12

CPC classification number: C07D211/46 ,  C07C317/32 ,  C07D211/32 ,  C07D307/14 ,  C07D309/06 ,  C07D319/12

Abstract: The application relates to a compound of Formula (I′) or (I):




or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

公开(公告)号：US11891369B2

公开(公告)日：2024-02-06

申请号：US16861166

申请日：2020-04-28

Applicant: SRX Cardio, LLC

Inventor： Anjali Pandey ,  Simeon Bowers ,  Thomas E. Barta ,  Jonathan William Bourne

IPC: A61K31/4709 ,  C07D295/073 ,  C07D401/04 ,  C07D403/04 ,  C07D211/18 ,  C07D211/26 ,  C07D211/46 ,  C07D211/54 ,  C07D211/58 ,  C07D295/195 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/02 ,  C07D417/04 ,  C07D417/14 ,  C07D471/08

CPC classification number: C07D295/073 ,  C07D211/18 ,  C07D211/26 ,  C07D211/46 ,  C07D211/54 ,  C07D211/58 ,  C07D295/195 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D407/02 ,  C07D417/04 ,  C07D417/14 ,  C07D471/08

Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity, for treatment of a disease or condition mediated, at least in part, by PCSK9. The compounds of the disclosure include compounds Formula (I).

公开(公告)号：US11873288B2

公开(公告)日：2024-01-16

申请号：US17112713

申请日：2020-12-04

Applicant: The Regents of the University of California

Inventor： Bruce Hammock ,  Sean Kodani

IPC: C07D401/06 ,  C07C275/28 ,  C07D271/10 ,  C07C275/34 ,  A61P35/00 ,  C07C275/36 ,  C07D211/16 ,  C07D211/46 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/04

CPC classification number: C07D401/06 ,  A61P35/00 ,  C07C275/28 ,  C07C275/34 ,  C07C275/36 ,  C07D211/16 ,  C07D211/46 ,  C07D271/10 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/04 ,  C07C2601/14

Abstract: The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

公开(公告)号：US11767303B2

公开(公告)日：2023-09-26

申请号：US17384051

申请日：2021-07-23

Applicant: Health Research, Inc. ,  Arizona Board of Regents on Behalf of the University of Arizona ,  Board of Regents, The University of Texas System

Inventor： Hongmin Li ,  Zhong Li ,  Jia Zhou ,  Jimin Xu ,  Qing-Yu Zhang

IPC: A61K31/5375 ,  C07D265/30 ,  C07C233/75 ,  C07D211/46 ,  A61P31/14 ,  C07D409/12 ,  C07D213/75 ,  C07D333/54

CPC classification number: C07D265/30 ,  A61P31/14 ,  C07C233/75 ,  C07D211/46 ,  C07D213/75 ,  C07D333/54 ,  C07D409/12

Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.

公开(公告)号：US11685718B2

公开(公告)日：2023-06-27

申请号：US17551806

申请日：2021-12-15

Applicant: Amicus Therapeutics, Inc.

Inventor： Kamlesh Sheth ,  Sergey Tesler ,  James Cartwright ,  Clive King ,  Wendy Cross

IPC: C07D211/46

CPC classification number: C07D211/46 ,  C07B2200/13

Abstract: Provided are methods of producing Active Pharmaceutical Ingredient (API) grade migalastat hydrochloride, and for purifying intermediate grade migalastat hydrochloride. Further provided are methods of producing [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride (lucerastat hydrochloride) and other 1-deoxygalactonojirimycin compounds, as well as methods of purifying intermediate grade lucerastat hydrochloride and other 1-deoxygalactonojirimycin compounds.

公开(公告)号：US20230174486A1

公开(公告)日：2023-06-08

申请号：US17923875

申请日：2021-05-06

Applicant: ALECTOS THERAPEUTICS lNC.

Inventor： Ramesh KAUL ,  Ernest J. MCEACHERN ,  Jianyu SUN ,  David J. VOCADLO ,  Yuanxi ZHOU ,  Yongbao ZHU

IPC: C07D211/46 ,  C07D401/06 ,  C07D409/06 ,  C07D405/10 ,  C07D417/14 ,  C07D401/14 ,  C07D405/06 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D211/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D405/06 ,  C07D405/10 ,  C07D409/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

公开(公告)号：US20230090562A1

公开(公告)日：2023-03-23

申请号：US17813382

申请日：2022-07-19

Applicant: GEN1E LIFESCIENCES INC.

Inventor： ADAM GALAN ,  WENDY LUO ,  RITU LAL

IPC: C07D491/107 ,  A61P31/14 ,  C07D207/12 ,  C07D211/42 ,  C07D211/46 ,  C07D239/30 ,  C07D241/08 ,  C07D265/30 ,  C07D267/10 ,  C07D491/048 ,  C07D498/18

Abstract: Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38α mitogen-activated protein kinase inhibitors.

公开(公告)号：US20220411371A1

公开(公告)日：2022-12-29

申请号：US17762443

申请日：2020-09-23

Applicant: TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Inventor： Anantha Rajmohan Muthusamy ,  Sundara Lakshmi Kanniah ,  Yogesh Dhananjay Wagh

IPC: C07D211/46

Abstract: The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.